Skip to content
Screener

Total Revenue at other companies

CareDx logo
CareDxCDNA
$117.7M+39.0%
Guardant Health logo
Guardant HealthGH
$301.67M+48.3%
Natera, Inc. logo
Natera, Inc.NTRA
$752.75M+37.7%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$71.14M-3.2%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$592.1M+1.1%
Agilent Technologies logo
Agilent TechnologiesA
$1.88B+8.1%

Segments

By geography

See full
Europe$15K-37.5%
Asia Pacific$6K

Other financials

Income statement

See full
Gross profit$157.0K-53.6%
Operating income-$11.4M-15.9%
Net income-$11.3M-15.6%
EPS (diluted)-$0.31-3.3%

Balance sheet

See full
Cash & equivalents$17.8M-26.9%
Total debt$2.4M-23.5%
Total equity-$21.3M-2,040%
Total assets$29.4M-41.7%

Cash flow

See full
Operating cash flow-$9.3M-50.1%
CapEx$779.0K+123%
Free cash flow-$10.0M-54.0%

Valuation

See full
Market cap$140.71M+98.3%
Enterprise value$125.4M+151%
P/S84.3×+67.6×

Profitability

See full
Gross margin48.3%-6.9pp
Operating margin-3,011.9%-299,142pp
Net margin-2,955.6%+182,096pp
FCF margin-1,856.2%-3,270pp

Returns & leverage

See full
Return on equity-532.9%-717pp
Debt / equity2.9×+2.8×
Current ratio-2.0×

Where this comes from

Reported directly by Insight Molecular Diagnostics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Insight Molecular Diagnostics Inc.’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001642380-26-000011
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net revenue$239$518$271$2,656
Cost of revenues8218099993
Gross profit1573381721,663
Operating expenses:
Research and development4,4863,2699,4396,193
Sales and marketing1,9161,4604,3182,666
General and administrative2,8732,6475,8645,762
Change in fair value of contingent consideration2,2842,804(3,634)3,683

Item 1. Financial Statements.

FAQ

What is Insight Molecular Diagnostics Inc.'s total revenue?
Insight Molecular Diagnostics Inc. (IMDX) reported total revenue of $239K in Q2 2026.
How has Insight Molecular Diagnostics Inc.'s total revenue changed year-over-year?
Insight Molecular Diagnostics Inc.'s total revenue decreased by 53.9% year-over-year, from $518K to $239K.
What is the long-term trend for Insight Molecular Diagnostics Inc.'s total revenue?
Over 4 years (2021 to 2025), Insight Molecular Diagnostics Inc.'s total revenue has grown at a -14.9% compound annual growth rate (CAGR), from $7.73M to $4.06M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Insight Molecular Diagnostics Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude